New strategies in the treatment and prevention of allergic diseases

Bibliography

• NATIONAL INSTITUTE OF HEALTH AND NATIONAL HEART LABI: Global strategy for asthma management and prevention guidelines. (2002) Report number: 02–3659:a1–176.
   Google Scholar
• ••This report covers asthma from A to Zincluding a six-part asthma management programme.
   Google Scholar
• LOCKEY R: 'ARIA': Global guidelines and new forms of allergen immunotherapy. Allergy Clin. Immunol (2001) 108:497–499.
   Google Scholar
• ••This is a comprehensive report about allergicrhinitis including management guidelines.
   Google Scholar
• LITONJUA A, CAREYV, BURGE H, WEISS S, GOLD D: Exposure to cockroach allergen in the home is associated with incident doctor-diagnosed asthma and recurrent wheezing. I Allergy Clin. Immunol (2001) 107:41–47.
   PubMed Web of Science ®Google Scholar
• LAU S, ILLI S, SOMMERFELD C et al: Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group. Lancet (2000) 356:1392–1397.
   PubMed Web of Science ®Google Scholar
• PLATTS-MILLS T, VAUGHAN J, SQUILLACE S, WOODFOLK J, SPORIK R: Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet (2001) 357:752–756.
   PubMed Web of Science ®Google Scholar
• BALL TM, CASTRO-RODRIGUEZ JA, GRIFFITH KA, HOLBERG CJ, MARTINEZ FD, WRIGHT AL: Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl. Med. (2000) 343:538–543.
   PubMed Web of Science ®Google Scholar
• RIEDLER J, BRAUN-FAHRLANDER C, EDER W et al.: Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet (2001) 358:1129–1133.
   PubMed Web of Science ®Google Scholar
• BRAUN-FAHRLANDER C, RIEDLER J, HERZ U et al.: Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl.' Med. (2002) 347:869–877.
   PubMed Web of Science ®Google Scholar
• KAY AB: Allergy and allergic diseases first oftwo parts. N Engl. I Med. (2001) 344:30–37.
   PubMed Web of Science ®Google Scholar
• •This is an excellent review about the basic principles of allergy and AD.
   Google Scholar
• YAZDANBAKHSH M, KREMSNER PG, VAN REE R: Allergy, parasites, and the hygiene hypothesis. Science (2002) 296:490–494.
   PubMed Web of Science ®Google Scholar
• ••This review discusses the role of theregulatory or anti-inflammatory network in the hygiene hypothesis.
   Google Scholar
• WILLS-KARP M, SANTELIZ J, KARP CL: The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev brimunol. (2001) 1:69–75.
   PubMed Web of Science ®Google Scholar
• UMETSU DT, McINTIRE JJ, AKBAR 0, MACAUBAS C, DEKRUYFF RH: Asthma: an epidemic of dysregulated immunity. Nat. Immun. (2002) 3:715–720.
   Google Scholar
• ••This review discusses the role of regulatoryT cells as a promoter of protective immunity and tolerance to respiratory allergens. The authors also highlight some potential new immune-based therapies for asthma.
   Google Scholar
• BRITISH THORACIC SOCIETY (BTS), SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK (SIGN): British guideline on the management of asthma. Thorax (2003) 58:il-i94.
   Google Scholar
• ••This supplement contains the BritishThoracic Society and Scottish Intercollegiate Guidelines Network 2003 guidelines on the management of asthma.
   Google Scholar
• LAZARUS SC, BOUSHEY HA, FAHYJV et al.: Long-actingl32-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA (2001) 285:2583–2593.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Scientific rationale for inhaled combination therapy with long-acting 32-agonists and corticosteroids. Ear: Respic (2002) 19:182–191.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, BARNES PJ, RODRIGUEZ-ROISIN R et al.: Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am. I Respir. Grit. Care Med. (2001) 164:1392–1397.
   Google Scholar
• PALMQVIST M, ARVIDSSON P, BECKMAN 0, PETERSON S, LOTVALL J: Onset of bronchodilation of budesonide/formoterol versus salmeterol/ fluticasone in single inhalers. Pulm. Pharmacol Ther. (2001) 14:29–34.
   PubMed Web of Science ®Google Scholar
• VAN VEEN A, WELLER FR, WIERENGA EA, JANSEN HM, JONKERS RE: A comparison of salmeterol and formoterol in attenuating airway responses to short-actingl32-agonists. Pulm. Pharmacol Ther. (2003) 16:153–161.
   PubMed Web of Science ®Google Scholar
• DAVIS BE, REID JK, COCKCROFT DW: Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection. Can. Respic (2003) 10:23–26.
   PubMedGoogle Scholar
• TATTERSFIELD AE, LOFDAHL CG, POSTMA DS et al.: Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet (2001) 357:257–261.
   PubMed Web of Science ®Google Scholar
• HANDLEY DA, ANDERSON AJ, KOESTER J, SNIDER ME: New millennium bronchodilators for asthma: single-isomer Pagonists. Curt: Opin. Pulm. Med. (2000) 6:43–49.
   PubMedGoogle Scholar
• MILGROM H, SKONER D, BENSCH G, KIM K, CLAUS R, BAUMGARTNER R: Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. Allergy Clin. Immunol (2001) 108:938–945.
   Google Scholar
• LOTVALL J, PALMQVIST M, ARVIDSSON P, MALONEY A, VENTRESCA G, WARD J: The therapeutic ratio of R-albuterol is comparable with that of R..Calbuterol in asthmatic patients. I Allergy Clin. Immunol (2001) 108:726–731.
   PubMed Web of Science ®Google Scholar
• XIE QM, CHEN JQ, SHEN WH, YANG QH, BIAN RL: Comparison of bronchodilating and antiinflammatory activities of oral formoterol and its (R,R) enantiomers. Acta Pharmacol SM. (2003) 24:277–282.
   Web of Science ®Google Scholar
• DENT G: Ciclesonide (Byk Gulden). Can: Opin. Investig. Drugs (2002) 3:78–83.
   PubMed Web of Science ®Google Scholar
• WEINBRENNER A, HUNEKE D, ZSCHIESCHE M et al.: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. I Clin. Endocrinol Metab. (2002) 87:2160–2163.
   PubMed Web of Science ®Google Scholar
• KANNIESS F, RICHTER K, BOHME S, JORRES RA, MAGNUSSEN H: Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm. Pharmacol The]: (2001) 14:141–147.
   PubMed Web of Science ®Google Scholar
• LARSEN BB, NIELSEN LP, ENGELSTATTER R, STEINIJANSV, DAHL R: Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy (2003) 58:207–212.
   PubMed Web of Science ®Google Scholar
• POSTMA DS, SEVETTE C, MARTINAT Y, SCHLOSSER N, AUMANN J, KAFE H: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Ear. Respic (2001) 17:1083–1088.
   Google Scholar
• SCHMIDT BM, TIMMER W, GEORGENS AC et al.: The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. I Clin. Pharmacol (1999) 39:1062–1069.
   PubMed Web of Science ®Google Scholar
• BODOR N: Retrometabolic drug design novel aspects, future directions. Pharmazie (2001) 56\(Suppl. 1):S67–S74.
   Google Scholar
• BODOR N, BUCHWALD P: Soft drug design: general principles and recent applications. Med. Res. Rev (2000) 20:58–101.
   PubMed Web of Science ®Google Scholar
• VAYSSIERE BM, DUPONT S, CHOQUART A et al.: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol (1997) 11:1245–1255.
   PubMed Web of Science ®Google Scholar
• BELVISI MG, WICKS SL, BATTRAM CH et al.: Therapeutic benefit of a dissociated glucocorticoid and the relevance of M vitro separation of transrepression from transactivation activity. Immunol (2001) 166:1975–1982.
   Web of Science ®Google Scholar
• CHUNG KF, BARNES PJ: Cytokines in asthma. Thorax (1999) 54:825–857.
   PubMed Web of Science ®Google Scholar
• •This review discusses the role of cytokines in the pathogenesis of asthma.
   Google Scholar
• BARNES PJ: Cytokine modulators as novel therapies for asthma. Ann. Rev Pharmacol Toxicol (2002) 42:81–98.
   PubMed Web of Science ®Google Scholar
• ••This paper discusses new and potentialnew agents that modulate cytokines in asthma.
   Google Scholar
• FOSTER PS, HOGAN SP, YANG M et al.:Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Ma Med. (2002) 8:162–167.
   PubMed Web of Science ®Google Scholar
• LECKIE MJ, TEN BRINKE A, KHAN J et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2144–2148.
   PubMed Web of Science ®Google Scholar
• FLOOD-PAGE P, MENZIES-GOW A, PHIPPS S et al.: Reduction of tissue eosinophils in mild atopic asthmatics by an anti-i1-5 monoclonal antibody (mepolizumab) is associated with inhibition of tenascin deposition within the bronchial epithelial basement membrane. Am. J. Respir. Grit. Care Med. (2002) 165:B42.
   Google Scholar
• FLOOD-PAGE PT, MENZIES-GOW AN,KAY AB, ROBINSON DS: Eosinophirs role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respic Grit. Care Med. (2003) 167:199–204.
   PubMed Web of Science ®Google Scholar
• FLOOD-PAGE P, MENZIES-GOW A, PHIPPS S et al: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. Clin. Invest. (2003) 112:1029–1036.
   Google Scholar
• •This study demonstrates the potential role of eosinophils and anti-IL-5 treatment in asthma airway remodelling.
   Google Scholar
• KIPS JC, O'CONNOR BJ, LANGLEY SJ et al: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. Respic Crit. Care Med. (2003) 167:1655–1659.
   PubMed Web of Science ®Google Scholar
• KAY AB, MENZIES-GOW A: Eosinophilsand interleukin-5: the debate continues. Am. I Respir. Grit. Care Med. (2003) 167:1586–1587.
   PubMed Web of Science ®Google Scholar
• STEINKE J, BORISH L: Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir. Res. (2001) 2:66–70.
   Google Scholar
• •This paper is an excellent review of the pathophysiological role of IL-4 in asthma.
   Google Scholar
• SNELL NJ: Interleuldn-4 as a therapeutic target in allergic disorders. Carr. Opin. Anti-inflamm. Immunomodulatory Investig. Drugs (2000) 2:92–99.
   Google Scholar
• ••This paper covers the pathophysiology ofIL-4 and IL-13 receptors and IL-4 muteins as IL-4 and IL-13 antagonists in AD.
   Google Scholar
• BORISH LC, NELSON HS, LANZ MJ et al.: Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial. Am. J. Respir. Grit. Care Med. (1999) 160:1816–1823.
   PubMed Web of Science ®Google Scholar
• BORISH L, NELSON H, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. Allergy Clin. Immunol (2001) 107:963–970.
   Google Scholar
• GRUNEWALD SM, WERTHMANN A, SCHNARR B et al.: An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo.' Immunol (1998) 160:4004–4009.
   Web of Science ®Google Scholar
• HARRIS P, LINDELL D, FITCH N, GUNDEL N: The IL-4 receptor antagonist (Bay 16-9996) reverses airway hyperresponsiveness in a primate model of asthma. Am. I Respir. Crit. Care Med. (1999) 159:A230.
   Web of Science ®Google Scholar
• WILLS-KARP M, CHIARAMONTE M: Interleukin-13 in asthma. Carr: Opin. Pulm. Med. (2003) 9:21–27.
   Google Scholar
• ••This review explores the currentunderstanding of the role of IL-13 in the pathogenesis of allergy and asthma.
   Google Scholar
• GRUNIG G, WARNOCK M,WAKIL AE et al: Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 282:2261–2263.
   PubMed Web of Science ®Google Scholar
• •This report demonstrates the effective selective neutralisation of IL-13 with a sIL-13R as a new therapeutic approach for asthma.
   Google Scholar
• BARNES PJ: Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev (2003) 14:511–522.
   PubMed Web of Science ®Google Scholar
• SHAH A, CHURCH MK, HOLGATE ST: Tumour necrosis factor a: a potential mediator of asthma. Clin. Exp. Allergy (1995) 25:1038–1044.
   PubMed Web of Science ®Google Scholar
• THOMAS PS, YATES DH, BARNES PJ: Tumor necrosis factor-a increases airway responsiveness and sputum neutrophilia in normal human subjects. Am. Respir. Crit. Care Med. (1995) 152:76–80.
   PubMed Web of Science ®Google Scholar
• KHALIL SAADEH C, BROWN D, CHUMNEY-MALACARA J, CROW J: Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD in addition to improving RA status. I Allergy Clin. Immunol (2002) 109:A741.
   Google Scholar
• ••This is the first report about the beneficialpulmonary effects of infliximab, a TNF-a antagonist, in the management of RA with concomitant asthma/COPD.
   Google Scholar
• BABU KS, ARSHAD SH, HOWARTH PH et al: Soluble tumor necrosis factor a (TNF-a) Receptor (Enbrel) as an effective therapeutic strategy in chronic severe asthma. I Allergy Clin. Immunol (2003) 111:S277.
   Google Scholar
• ••This report of a pilot study usingetanercept, a soluble TNF-a receptor, for the treatment of patients with severe asthma demonstrates the beneficial effects of this novel asthma therapy.
   Google Scholar
• BRYAN S, LECKIE MJ, KHAN Jet al.: Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2149–2153.
   Google Scholar
• SUR S, BOUCHARD P, HOLBERT D, VAN SCOTT MR: Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma. Exp. Lung Res. (2000) 26:477–489.
   PubMed Web of Science ®Google Scholar
• LACK G, BRADLEY KL, HAMELMANN E et al.: Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. .1. Immunol (1996) 157:1432–1439.
   Google Scholar
• BOGUNIEWICZ M, MARTIN R, MARTIN D et al: The effects of nebulized recombinant interferon- [7] in asthmatic airways. J. Allergy Clin. Immunol (1995) 95:133–135.
   PubMed Web of Science ®Google Scholar
• MERITET JF, MAURY C, TOVEY MG: Effect of oromucosal administration of IFN-a on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen. .1. Interferon Cytokine Res. (2001) 21:583–593.
   PubMed Web of Science ®Google Scholar
• GRATZL S, PALCA A, SCHMITZ M, SIMON HU: Treatment with IFN-[a] in corticosteroid-unresponsive asthma. Allergy Clin. Immunol (2000) 105:1035–1036.
   Google Scholar
• BUSSE WW, LEMANSKE RF: Asthma. N Engl. Med. (2001) 344:350–362.
   PubMed Web of Science ®Google Scholar
• ••This is an excellent review of thepathophysiology of asthma.
   Google Scholar
• LLOYD C: Chemokines in allergic lung inflammation. Immunology (2002) 105:144–154.
   PubMed Web of Science ®Google Scholar
• BLEASE K, LUKACS NW, HOGABOAM CM, KUNKEL SL: Chemokines and their role in airway hyper-reactivity. Respir. Res. (2000) 1:54–61.
   PubMedGoogle Scholar
• YING S, MENG Q, ZEIBECOGLOU K et al.: Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. .1. Immunol (1999) 163:6321–6329.
   Google Scholar
• FERNANDEZ EJ, LOLIS E: Structure, function, and inhibition of chemokines. Ann. Rev Pharmacol Toxicol (2002) 42:469–499.
   PubMed Web of Science ®Google Scholar
• ••This review covers all subfamilies ofchemokines and discusses the different inhibitors and their activity.
   Google Scholar
• DYKE HJ, MONTANA JG: Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs (2002) 11:1–13.
   PubMed Web of Science ®Google Scholar
• •This review is an excellent update about the anti-inflammatory potential of PDE4 inhibitors in the treatment of inflammatory diseases.
   Google Scholar
• TORPHY TJ, BARNETTE MS, UNDERWOOD DC et al: Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Palm. Pharmacol Ther. (1999) 12:131–135.
   PubMed Web of Science ®Google Scholar
• ••This is a comprehensive review of thedifferent PDEs and inhibitors and their role in disease.
   Google Scholar
• New Drugs for Asthma, Allergy and COPD. Hansel T, Barnes PJ (Eds), S. Karger AG, Basel, Switzerland (2001):I–389.
   Google Scholar
• ••This is an excellent reference book for newagents and their developmental stage for the treatment of asthma, allergy and COPD.
   Google Scholar
• TIMMER W, LECLERC V, BIRRAUX G et al.: The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-a ex vivo. Clin. Pharmacol (2002) 42:297–303.
   Google Scholar
• SCHMIDT B, KUSMA M, FEURING M et al.: The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. I Allergy Clin. Immunol (2001) 108:530–536.
   PubMed Web of Science ®Google Scholar
• BAUMER W, GORR G, HOPPMANN J, EHINGER AM, EHINGER B, KIETZMANN M: Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD-12-281 on the inflammatory reaction in a model of allergic dermatitis. Eur. Pharmacol (2002) 446:195–200.
   PubMed Web of Science ®Google Scholar
• DRAHEIM R, EGERLAND U, RUNDFELDT C: Anti-inflammatory potential of the selective PDE4 inhibitor N-(3,5-dichloro-pyrid-4-y1)- [1- (4-fluorobenzyl) -5 - hydroxy-indole 3 glyoxylic acid amide (AWD-12-281), in human cell preparations. Pharmacol Exp. The]: (2004) (In press).
   Google Scholar
• REIMUND JM, RABOISSON P, PINNA G, LUGNIER C, BOURGUIGNON JJ, MULLER CD: Anti-TNF-a properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties. Biochem. Biophys. Res. Commun. (2001) 288:427–434.
   PubMed Web of Science ®Google Scholar
• ODA N, MINOGUCHI K, TANAKA A et al.: Suplatast tosilate inhibits thymus- and activation-regulated chemokine production by antigen-specific human Th2 cells. Clin. Exp. Allergy (2002) 32:1782–1786.
   PubMed Web of Science ®Google Scholar
• HORIGUCHI T, TACHIKAWA S, HANDA M et al: Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness. Asthma (2001) 38:331–336.
   Google Scholar
• TAMAOKI J, KONDO M, SAKAI N et al.: Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid- dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group. Lancet (2000) 356:273–278.
   PubMed Web of Science ®Google Scholar
• ••This is the first report of the beneficialclinical effect of suplatast tosilate, a TH2 cytokine inhibitor, in the therapy of patients with steroid-dependent asthma.
   Google Scholar
• TAMAOKI J, TAKEYAMA K, AOSHIBA K, NAKATA J, NISHIMURA K, NAGAI A: A Th2 cytokine inhibitor for airway inflammation in mild asthma. I Allergy Clin. Immunol (2003) 111:197–198.
   PubMed Web of Science ®Google Scholar
• SANO Y, SUZUKI N, YAMADA H et al: Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. I Allergy Clin. Immunol (2003) 111:958–966.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, AIZAWA H, INOUE H et al.: Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients. Asthma (2002) 39:545–552.
   Google Scholar
• SHIOYA T, SATAKE M, SANO M et al.: Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma. Eui: Clin. Pharmacol (2002) 58:171–176.
   Google Scholar
• WASHIO Y, OHASHI Y, TANAKA A et al.: Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis. Acta Otolaryngol Sapp]. (1998) 538:126–132.
   PubMedGoogle Scholar
• KIMATA H: Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann. Allergy Asthma Immunol (1999) 82:293–295.
   PubMed Web of Science ®Google Scholar
• LEE JC, KUMAR S, GRISWOLD DE, UNDERWOOD DC, VOTTA BJ, ADAMS JL: Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology (2000) 47:185–201.
   PubMed Web of Science ®Google Scholar
• •This is an excellent review about p38 MAPK; its homologues, substrates, signalling pathways, role in cytokine a production, role in haematopoietic cell, role in disease, inhibitors and perspectives.
   Google Scholar
• BARNES PJ, ADCOCK IM: Transcription factors and asthma. Ear: Respic J. (1998) 12:221–234.
   PubMed Web of Science ®Google Scholar
• KISHORE N, SOMMERS C, MATHIALAGAN S et al: A selective IKK-2 inhibitor blocks NE-NIB-dependent gene expression in interleukin-1{13}-stimulated synovial fibroblasts. J. Biol. Chem. (2003) 278:32861–32871.
   PubMed Web of Science ®Google Scholar
• BURKE JR, PATTOLI MA, GREGOR KR et al.: BMS-345541 is a highly selective inhibitor of IK-B-kinase that binds at an allosteric site of the enzyme and blocks NE-KB-dependent transcription in mice. Biol Chem. (2003) 278:1450–1456.
   Web of Science ®Google Scholar
• DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl. J. Med. (1999) 340:197–206.
   PubMed Web of Science ®Google Scholar
• •This paper reviews the role of LT inhibitors in the management of asthma.
   Google Scholar
• SALVI SS, KRISHNA MT, SAMPSON AP, HOLGATE ST: The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest (2001) 119:1533–1546.
   PubMed Web of Science ®Google Scholar
• •See reference [89].
   Google Scholar
• THOMSON NC, SHEPHERD M: Leukotriene receptor antagonists as add-on therapy for adults with asthma. Thorax (2003) 58:190–192.
   PubMed Web of Science ®Google Scholar
• NATHAN RA: Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann. Allergy Asthma Immunol (2003) 90:182–190.
   PubMed Web of Science ®Google Scholar
• WU AY, CHIK SC, CHAN AW, LIZ, TSANG KW, LI W: Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin. Exp. Allergy (2003) 33:359–366.
   PubMed Web of Science ®Google Scholar
• CAMARGO CA Jr, SMITHLINE HA, MALICE MP, GREEN SA, REISS TF: A randomized controlled trial of intravenous montelukast in acute asthma. Am. J. Respic Grit. Care Med. (2003) 167:528–533.
   PubMed Web of Science ®Google Scholar
• •This paper discusses the results of a pilot study of intravenous montelukast in acute asthma, which shows beneficial effects and good tolerability.
   Google Scholar
• REIMERS A, PICHLER C, HELBLING A, PICHLER WJ, YAWALKAR N: Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Gin. Exp. Allergy (2002) 32:1763–1768.
   PubMed Web of Science ®Google Scholar
• ERBAGCI Z: The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J. Allergy Clin. Immunol (2002) 110:484–488.
   PubMed Web of Science ®Google Scholar
• HEISE CE, O'DOWD BE FIGUEROA DJ et al.: Characterization of the human cysteinyl leukotriene 2 receptor. Biol. Chem. (2000) 275:30531–30536.
   Google Scholar
• NICOSIA S, CAPRA V, ROVATI GE: Leukotrienes as mediators of asthma. Palm. Pharmacol Ther. (2001) 14:3–19.
   PubMed Web of Science ®Google Scholar
• ••This review discusses the role of LTs in thepathogenesis of asthma and the effects of anti-LT drugs.
   Google Scholar
• BARNES PJ: Histamine and serotonin. Pulm. Pharmacol The]: (2001) 14:329-339. loft LEURS R, CHURCH MK, TAGLIALATELA M: Hl-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Gin. Exp. Allergy (2002) 32:489–498.
   Google Scholar
• ••This review discusses the coexistence ofactive and inactive histamine GPCRs and the role of H1-antihistamines as inverse agonists.
   Google Scholar
• MINCARINI M, PASQUALI M, COSENTINO C et al.: Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives. Palm. Pharmacol Ther. (2001) 14:267–276.
   PubMed Web of Science ®Google Scholar
• VAN GANSE E, KAUFMAN L, DERDE MP, YERNAULT JC, DELAUNOIS L, VINCKEN W: Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Ear: Respic (1997) 10:2216–2224.
   PubMed Web of Science ®Google Scholar
• SALMUN LM: Antihistamines in late-phase clinical development for allergic disease. Expert Opin. Investig. Drugs (2002) 11:259–273.
   PubMed Web of Science ®Google Scholar
• FOZARD JR: BP-294 STE civile bioprojet. CLIFF. Opin. Investig. Drugs (2000) 1:86–89.
   PubMedGoogle Scholar
• SAMPSON AP, RORKE S: Combination therapy with anti-mediator drugs in allergic disease. Gin. Exp. Allergy (2001) 31:11-17. los. REICIN A, WHITE R, WEINSTEIN SF et al.: Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch. Intern. Med. (2000) 160:2481–2488.
   Google Scholar
• COUTURE R, HARRISSON M, VIANNA RM, CLOUTIER F: Kinin receptors in pain and inflammation. Eur. J. Pharmacol (2001) 429:161–176.
   PubMed Web of Science ®Google Scholar
• HIRAYAMA Y, KAYAKIRI H: [Bradyldnin antagonist: current status and perspective]. Nippon Yakurigaku Zasshi (2002) 119:45-53. los. AKBARY AM, WIRTH KJ, SCHOLKENS BA: Efficacy and tolerability of icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology (1996) 33:238–242.
   Google Scholar
• TURNER P, DEAR J, SCADDING G, FOREMAN J: Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B(2) receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J. Allergy Gin. Immunol (2001) 107:105–113.
   PubMed Web of Science ®Google Scholar
• BROIDE DH, GLEICH GJ, CUOMO AJ et al.: Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J. Allergy Clin. Immunol (1991) 88:637–648.
   PubMed Web of Science ®Google Scholar
• FERGUSON AC, WHITELAW M, BROWN H: Correlation of bronchial eosinophil and mast cell activation with bronchial hyperresponsiveness in children with asthma. J. Allergy Clin. Immunol (1992) 90:609–613.
   PubMed Web of Science ®Google Scholar
• SOMMERHOFF CP: Mast cell tryptases and airway remodeling. Am. J. Respic Grit. Care Med. (2001) 164:S52–S58.
   PubMed Web of Science ®Google Scholar
• •This review discusses the role of tryptase, released from mast cells, in airway inflammation.
   Google Scholar
• KRISHNA M, CHAUHAN A, LITTLE L et al.: Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J. Allergy Clin. Immunol (2001) 107:1039–1045.
   PubMed Web of Science ®Google Scholar
• SUTTON JC, BOLTON SA, HARTL KS et al.: Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:3229–3233.
   PubMed Web of Science ®Google Scholar
• SANDERS SP: Nitric oxide in asthma. pathogenic, therapeutic, or diagnostic? Am. Respic Cell MM. Biol. (1999) 21:147–149.
   PubMed Web of Science ®Google Scholar
• FOLKERTS G, KLOEK J, MUIJSERS RB, NIJKAMP FP: Reactive nitrogen and oxygen species in airway inflammation. Eui: Pharmacol (2001) 429:251–262.
   PubMed Web of Science ®Google Scholar
• GUO FH, COMHAIR SAA, ZHENG S et al.: Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for
   Google Scholar
• Expert Opin. lnvestig. Drugs (2004) 13(2)
   Google Scholar
• •• transcriptional and post-translational regulation of no synthesis. J. Immunol (2000) 164:5970–5980.
   Google Scholar
• DE SANCTIS GT, MEHTA S, KOBZIK L et al.: Contribution of type I NOS to expired gas NO and bronchial responsiveness in mice. Am. I Physiol Lung Cell MM. PhysioL (1997) 273:L883–L888.
   PubMed Web of Science ®Google Scholar
• KOTARU C, SKOWRONSKI M, CORENO A, McFADDEN ER Jr: Inhibition of nitric oxide synthesis attenuates thermally induced asthma. AppL Physiol (2001) 91:703–708.
   PubMed Web of Science ®Google Scholar
• EYN OTT PR, GRONEBERG DA, CARAMORI G et al.: Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness. Eur. Pharmacol (2002) 452:123–133.
   PubMed Web of Science ®Google Scholar
• HANSEL TT, KHARITONOV SA, DONNELLY LE et al.: A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB (2003) 17:1298–1300.
   PubMed Web of Science ®Google Scholar
• HENRICKS PA, NIJKAMP FP: Reactive oxygen species as mediators in asthma. Pulm. Pharmacol Ther: (2001) 14:409–420.
   PubMed Web of Science ®Google Scholar
• SHAHEEN SO, STERNE JAC, THOMPSON RL, SONGHURST CE, MARGETTS BM, BURNEY PGJ: Dietary antioxidants and asthma in adults. population-based case-control study. Am. J. Respir: Crit. Care Med. (2001) 164:1823–1828.
   PubMed Web of Science ®Google Scholar
• ••This epidemiological study demonstratesthe importance of environmental factors such as diet in the phenotypic expression of asthma.
   Google Scholar
• BRITTON JR, PAVORD ID, RICHARDS KA et al.: Dietary antioxidant vitamin intake and lung function in the general population. Am. J. Respir. Crit. Care Med. (1995) 151:1383–1387.
   PubMed Web of Science ®Google Scholar
• MCKEEVER TM, SCRIVENER S, BROADFIELD E, JONES Z, BRITTON J, LEWIS SA: Prospective study of diet and decline in lung function in a general population. Am. J. Respir. Crit. Care Med. (2002) 165:1299–1303.
   PubMed Web of Science ®Google Scholar
• FOGARTY A, LEWIS S, WEISS S, BRITTON J: Dietary vitamin E, IgE concentrations, and atopy. Lancet (2000) 356:1573–1574.
   PubMed Web of Science ®Google Scholar
• TRENGA CA, KOENIG JQ, WILLIAMS PV: Dietary antioxidants and ozone-induced bronchial hyperresponsiveness in adults with asthma. Arch. Environ. Health (2001) 56:242–249.
   PubMedGoogle Scholar
• ROMIEU I, SIENRA-MONGE JJ, RAMIREZ-AGUILAR M et aL: Antioxidant supplementation and lung functions among children with asthma exposed to high levels of air pollutants. Am. Respir. Crit. Care Med. (2002) 166:703–709.
   PubMed Web of Science ®Google Scholar
• PETERS EA, HILTERMANN JTN, STOLK J: Effect of apocynin on ozone-induced airway hyperresponsiveness to methacholine in asthmatics. Free Radic. Biol. Med. (2001) 31:1442–1447.
   PubMed Web of Science ®Google Scholar
• NEUMAN I, NAHUM H, BEN AMOTZ A: Reduction of exercise-induced asthma oxidative stress by lycopene, a natural antioxidant. Allergy (2000) 55:1184–1189.
   PubMed Web of Science ®Google Scholar
• CHANG LY, CRAPO JD: Inhibition of airway inflammation and hyperreactivity by a catalytic antioxidant. Chest (2003) 123:4465-446a.
   Google Scholar
• BLESA S, CORTIJO J, MATA M et al: Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen. Eur: Respir J. (2003) 21:394–400.
   PubMed Web of Science ®Google Scholar
• PICADO C, DEULOFEU R, LLEONART R et al.: Dietary micronutrients/antioxidants and their relationship with bronchial asthma severity. Allergy (2001) 56:43–49.
   PubMed Web of Science ®Google Scholar
• KAY AB: Allergy and allergic diseases. Second of two parts. N Engl. J. Med. (2001) 344:109–113.
   PubMed Web of Science ®Google Scholar
• •This is an excellent review about allergy and AD and their treatment.
   Google Scholar
• FREW AJ: 25. Immunotherapy of allergic disease. I Allergy Clin. Immunol (2003) 111:S712–S719.
   Google Scholar
• ••This is an excellent review about the role ofspecific immunotherapy in the treatment of AD.
   Google Scholar
• WILSON DR, TORRES LI, DURHAM SR: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev (2003) 2: CD002893.
   Google Scholar
• DURHAM SR, WALKER SM, VARGA EM et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. (1999) 341:468–475.
   PubMed Web of Science ®Google Scholar
• MOLLER C, DREBORG S, FERDOUSI H et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). I Allergy Clin. Immunol (2002) 109:251–256.
   PubMed Web of Science ®Google Scholar
• BOUSQUET J: Pro: Immunotherapy is clinically indicated in the management of allergic asthma. Am. J. Respir: Crit. Care Med. (2001) 164:2139–2140.
   PubMed Web of Science ®Google Scholar
• ADKINSON NE, Jr: Con: Immunotherapy is not clinically indicated in the management of allergic asthma. Am. J. Respir. Crit. Care Med. (2001) 164:2140–2141.
   PubMed Web of Science ®Google Scholar
• ABRAMSON MJ, PUY RM, WEINER JM: Allergen immunotherapy for asthma. Cochrane Database Syst. Rev (2000) 2:CD001186.
   Google Scholar
• ••This systematic review discusses theusefulness of allergen immunotherapy in asthma.
   Google Scholar
• MORTEMOUSQUE B, BERTEL F, DE CASAMAYOR J, VERIN P, COLIN J: House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin. Exp. Allergy (2003) 33:464–469.
   PubMed Web of Science ®Google Scholar
• DI RIENZO V, MARCUCCI F, PUCCINELLI P et al: Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy (2003) 33:206–210.
   PubMed Web of Science ®Google Scholar
• CHAPMAN MD, SMITH AM, VAILES LD, POMES A: Recombinant allergens for immunotherapy. Allergy Asthma Proc. (2002) 23:5–8.
   PubMed Web of Science ®Google Scholar
• FELLRATH JM, KETTNER A, DUFOUR N et al: Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a Phase I trial. I Allergy Clin. ImmunoL (2003) 111:854–861.
   PubMed Web of Science ®Google Scholar
• KRIEG AM: CPG motifs in bacterial DNA and their immune effects. Ann. Rev Immunol (2002) 20:709–760.
   PubMed Web of Science ®Google Scholar
• HORNER A, PAZ E: Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. Allergy Clin. Immunol (2002) 110:706–712.
   Google Scholar
• AGRAWAL S, KANDIMALLA ER: Medicinal chemistry and therapeutic potential of CpG DNA. Trends MM. Med. (2002) 8:114–121.
   PubMed Web of Science ®Google Scholar
• FAHY JV, FLEMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and late- phase responses to allergen inhalation in asthmatic 122 Expert Op/n. Investig. Drugs (2004) 13(2) subjects. Am. I Respir. Crit. Care Med. (1997) 155:1828–1834.
   Google Scholar
• MILGROM H, FICK RB, SU JQ et al: Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl. I Med. (1999) 341:1966–1973.
   PubMed Web of Science ®Google Scholar
• •This paper confirms the beneficial effect of rhulVIAb-E25 in large randomised placebo-controlled trials.
   Google Scholar
• BUSSE W, CORREN J, LANIER B et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. brimunol. (2001) 108:184–190.
   PubMed Web of Science ®Google Scholar
• •See reference [151].
   Google Scholar
• SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Ear: Respir. (2001) 18:254–261.
   PubMed Web of Science ®Google Scholar
• •See reference [151].
   Google Scholar
• FINN A, GROSS G, VAN BAVEL J et al.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. I Allergy Clin. Immunol (2003) 111:278–284.
   Google Scholar
• •See reference [151].
   Google Scholar
• CORREN J, CASALE T, DENIZ Y, ASHBY M: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. I Allergy Clin. Immunol (2003) 111:87–90.
   PubMed Web of Science ®Google Scholar
• CASALE T: Experience with monoclonal antibodies in allergic mediated disease: Seasonal allergic rhinitis. J. Allergy Clin. brimunol. (2001) 108:84s–88s
   Google Scholar
• KUEHR J, BRAUBURGER J, ZIELEN S et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. I Allergy Clin. brimunol. (2002) 109:274–280.
   PubMed Web of Science ®Google Scholar
• LEUNG DYM, SAMPSON HA, YUNGINGER JW et al.: Effect of anti-IgE therapy in patients with peanut allergy N Engl. J. Med. (2003) 348:986–993.
   Google Scholar
• ••This excellent study demonstrates thebeneficial effects of a new humanised IgG1 monoclonal antibody against IgE in the treatment of patients with peanut allergy.
   Google Scholar
• WANG CY, WALFIELD AM, FANG X et al.: Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine (2003) 21:1580–1590.
   PubMed Web of Science ®Google Scholar
• EVANS DJ, CULLINAN P, GEDDES DM: Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst. Rev (2001) CD002993.
   Google Scholar
• ROHATAGI S, CALIC F, HARDING N et al.: Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. Clin. Pharmacol (2000) 40:1211–1226.
   Google Scholar
• KHAN LN, KON OM, MacFARLANE AJ et al.: Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. Am. I Respir. Grit. Care Med. (2000) 162:1377–1382.
   PubMed Web of Science ®Google Scholar
• ECKSTEIN JW, FUNG J: A new class of cyclosporin analogues for the treatment of asthma. Expert Opin. Investig. Drugs (2003) 12:647–653.
   PubMed Web of Science ®Google Scholar
• SCHROER B, LOCKEY R: Oral tacrolimus for severe recalcitrant atopic eczema. I Allergy Clin. Immunol (2003) 111:1409–1410.
   PubMed Web of Science ®Google Scholar
• EICHENFIELD L, BECK L: Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. .I. Allergy Clin. brimunol. (2003) 111:1153–1168.
   PubMed Web of Science ®Google Scholar
• SHIRAKAWA T, ENOMOTO T, SHIMAZU S, HOPKIN JM: The inverse association between tuberculin responses and atopic disorder. Science (1997) 275:77–79.
   PubMed Web of Science ®Google Scholar
• MARKS GB, NG K, ZHOU Jet al.: The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: an historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease. I Allergy Clin. Immunol (2003) 111:541–549.
   Google Scholar
• ARKWRIGHT P, DAVID T: Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. I Allergy Clin. Immunol (2001) 107:531–534.
   PubMed Web of Science ®Google Scholar
• SHIRTCLIFFE PM, EASTHOPE SE, CHENG SOO et al.: The effect of delipidated deglycolipidated (DDMV) and heat-killed mycobacterium vaccae in asthma. Am. I Rapti: Crit. Care Med. (2001) 163:1410–1414.
   PubMed Web of Science ®Google Scholar
• CAMPOROTA L, CORKHILL A, LONG H et al.: The effects of mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Ear: Respir. 1 (2003) 21:287-293.
   Google Scholar
• CHOI IS, KOH YI: Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann. Allergy Asthma Immunol (2002) 88:584–591.
   PubMed Web of Science ®Google Scholar
• MURCH SH: Toll of allergy reduced by probiotics. Lancet (2001) 357:1057–1059.
   PubMed Web of Science ®Google Scholar
• CROSS ML, STEVENSON LM, GILL HS: Anti-allergy properties of fermented foods: an important immunoregulatory mechanism of lactic acid bacteria? Int. Immunopharmacol (2001) 1:891–901.
   PubMed Web of Science ®Google Scholar
• ISOLAURI E, ARVOLA T, SUTAS Y, MOILANEN E, SALMINEN S: Probiotics in the management of atopic eczema. Clin. Exp. Allergy (2000) 30:1604–1610.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates the potential usefulness of probiotics in the management of atopy.
   Google Scholar
• KALLIOMAKI M, SALMINEN S, ARVILOMMI H, KERO P, KOSKINEN P, ISOLAURI E: Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet (2001) 357:1076–1079.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated a significant reduced frequency of atopic dermatitis in children aged 2 years when probiotics were used as a preventative agent.
   Google Scholar
• KALLIOMAKI M, SALMINEN S, POUSSA T, ARVILOMMI H, ISOLAURI E: Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet (2003) 361: 1869-1871.
   Google Scholar
• •This is a follow-up report of the children at the age of 4 years from the study in reference [175].
   Google Scholar
• ROSENFELDT V, BENFELDT E, NIELSEN SD et al.: Effect of probiotic Lactobacillus strains in children with atopic dermatitis. I Allergy Clin. brimunol. (2003) 111:389–395.
   PubMed Web of Science ®Google Scholar
• OBER C: Susceptibility genes in asthma and allergy. Carr: Allergy Asthma Rep. (2001) 1:174–179.
   PubMedGoogle Scholar
• SENGLER C, LAU S, WAHN U, NICKEL R: Interactions between genes and environmental factors in asthma and atopy: new developments. Respir. Res. (2002) 3:7. This review covers the methodology of genetic studies of multifactorial diseases such as atopy and asthma and summarises the results thereof and the interactions with environmental factors.
   Google Scholar
• IANNUZZI M, MALIARIK M, RYBICKI B: Genetic polymorphisms in lung disease: bandwagon or breakthrough? Respir. Res. (2002) 3:15.
   Google Scholar
• HALL IP: Pharmacogenetics, pharmacogenomics and airway disease. Respir. Res. (2002) 3:10.
   PubMedGoogle Scholar
• NYCE JVV, METZGER WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385:721–725.
   PubMed Web of Science ®Google Scholar
• •This is an important study that demonstrated the therapeutic potential of respirable antisense oligonudeotides.
   Google Scholar
• SANDRASAGRA A, TANG L, LEONARD SA et al.: RASONs: a novel antisense oligonucleotide therapeutic approach for asthma. Expert Opin. Biol. Ther. (2001) 1:979–983.
   PubMed Web of Science ®Google Scholar
• WALL NR, SHI Y: Small RNA: can RNA interference be exploited for therapy? Lancet (2003) 362:1401–1403.
   PubMed Web of Science ®Google Scholar
• ••An excellent review about RNAi as a newgene therapy.
   Google Scholar
• ZAVOROTINSKAYA T, TOMKINSON A, MURPHY JE: Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13. Mel Ther. (2003) 7:155–162.
   PubMed Web of Science ®Google Scholar
• FACTOR P: Gene therapy for asthma. Mel Ther. (2003) 7:148–152.
   PubMed Web of Science ®Google Scholar
• SCHERR M, BATTMER K, BLOMER U et al.: Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/ SCID-repopulating cells. Blood (2002) 99:709–712.
   PubMed Web of Science ®Google Scholar
• KRAUSE DS, THEISE ND, COLLECTOR MI et al: Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell (2001) 105:369–377.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated that there are not only haematopoietic stem cells in the bone marrow.
   Google Scholar
• HERZOG EL, CHAI L, KRAUSE DS: Plasticity of marrow derived stem cells. Blood (2004) (In press).
   Google Scholar
• ••This review discusses the role of bonemarrow-derived mesenchymal stem cells in the differentiation of mature, non-haematopoietic cells, in multiple tissues including the lung, and highlights potential clinical applications.
   Google Scholar
• HOHLFELD J: The role of surfactant in asthma. Respir. Res. (2002) 3:4.
   PubMed Web of Science ®Google Scholar
• •This review demonstrates that surfactant is not just of interest in neonatology.
   Google Scholar
• BABU KS, WOODCOCK DA, SMITH SE, STANIFORTH JN, HOLGATE ST, CONWAY JH: Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Ear: Respir. 1(2003) 21:1046-1049.
   Google Scholar
• PERSIANI S, D'AMATO M, MAKOVEC F, ARSHAD SH, HOLGATE ST, ROVATI LC: Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Biopharm. Drug Dispos. (2001) 22:73–81.
   PubMed Web of Science ®Google Scholar
• SALVI SS, CASERINI M, D'AMATO M, ROVATI L, HOLGATE ST, ARSHAD H: Andolast reduces airway hyperresponsiveness (AHR) to adenosine 5'-monophospate (AMP) dose-dependently in mild atopic asthma. Am. I Respir. Crit. Care Med. (2002) 165:A188.
   Google Scholar
• KIMURA N, FUKUI H, TAKAGAKI H, YONEMOCHI E, TERADA K: Characterization of polymorphs of a novel quinolinone derivative, TA-270 (4-hydroxy-1-methy1-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone). Chem. Pharm. Bull. (Tokyo) (2001) 49:1321–1325.
   PubMed Web of Science ®Google Scholar
• AOKI Y, ISHIWARA M, KODA A, TAKAGAKI H: Inhibitory effect of a novel quinolinone derivative, TA-270, on asthmatic inflammatory responses in sensitized guinea pigs. Ear: I Pharmacol (2000) 409:325-330. Affiliation Hans Michael Haitchijr & Stephen T Holgate -rAuthor for correspondence University of Southampton, School of Medicine, Division of Infection, Inflammation & Repair, Respiratory, Cell & Molecular Biology, Level D, Centre Block, Mail Point 810, Southampton General Hospital, Southampton, S016 6YD, UK Tel: +44 (0)23 8079 4196; Fax: +44 (0)2380 701771; E-mail: [email protected] or [email protected]
   Google Scholar